Rare diseases
Investigational molecules
Locations
Long-Term Safety Study of Inhaled Pirfenidone for Patients with Progressive or Idiopathic Pulmonary Fibrosis
BelgiumStudy on the Effects of Wharton's Jelly Mesenchymal Stem Cells, Pirfenidone, and Nintedanib for Patients with Fibrotic Interstitial Lung Disease
PolandRandomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis
BelgiumA study to evaluate the effectiveness of upadacitinib and pirfenidone in reducing symptom severity in patients with Long Covid
ItalyStudy on Pirfenidone for Preventing Lung Fibrosis in Patients with Acute Respiratory Distress Syndrome (ARDS)
ItalyEffect of BI 1015550 on blood levels of nintedanib and pirfenidone in healthy men
GermanyStudy of Inhaled Pirfenidone for Patients with Progressive Pulmonary Fibrosis
BelgiumStudy on Pirfenidone Inhalation Solution for Patients with Progressive Fibrosing Interstitial Lung Diseases, Including Idiopathic Pulmonary Fibrosis
CzechiaStudy on Idiopathic Pulmonary Fibrosis: Evaluating Pirfenidone and Nintedanib for Patients with Progressive Disease
FranceStudy on the Effects of Deupirfenidone and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
GreeceTell us about your condition – we search every trial in Europe and connect you with the right site.
